There are several different cancer vaccine strategies in various stages of clinical development, and it is too early to tell which approach is superior to others in all situations. In fact, it is more likely that different types and stages of cancer will require different approaches. Typically, such vaccines are applied in an adjuvant setting, after surgery and other means have been applied to de-bulk the tumor mass. All strategies have one feature in common, and that is that they are composed of a method to deliver tumor associated antigens (TAA) to the immune system, together with immune-stimulants.
DCOne cells behave as the immortalized equivalents of DC precursor cells prepared from blood. Upon stimulation through a proprietary process, these immortal precursor DC differentiate and mature into fully functional DC that are able to induce specific T-cell and antibody responses that subsequently kill tumor cells. The DCOne cell line is derived from a patient with acute myeloid leukemia (AML) and expresses multiple AML-specific antigens. This makes the DCOne ideal for treatment of AML patients, since it does not need additional loading of tumor-specific antigens.
In addition to being applicable to treatment of AML, the DCOne platform’s most powerful feature is that, upon loading with any kind of TAA, it can be applied to many cancer indications. DCPrime has developed strategies to load the DCOne cell with genes or proteins or peptides from multiple antigens to which an immune response is required. Such antigen-loaded cells can be used alone or in fixed ratios and in different combinations, making the platform broadly applicable.
DCPrime uses its innovative DCOne platform to deliver TAA, and DCOne is based on a proprietary human dendritic cell line which is able to stimulate T-cells of the immune system to attack cancer cells, thereby aiming to cure the patient from cancer. Dendritic cells (DC) derived from patients are increasingly applied in the immunotherapy of cancer. With such patient-derived vaccines, the development of a standardized DC vaccine product is often hampered by limited availability of DC precursors and donor variability. Also, the preparation of individual vaccines is labor-intensive. It would be preferable therefore to have access to DC from a readily available and unlimited source, such as cell lines can provide. DCPrime developed the DCOne platform for that purpose, allowing the preparation of large quantities of standardized dendritic cells that provide an off-the-shelf alternative.
DCOne cells behave as the immortalized equivalents of DC precursor cells prepared from blood. Upon stimulation through a proprietary process, these immortal precursor DC differentiate and mature into fully functional DC that are able to induce specific T-cell and antibody responses that subsequently kill tumor cells. The DCOne cell line is derived from a patient with acute myeloid leukemia (AML) and expresses multiple AML-specific antigens. This makes the DCOne ideal for treatment of AML patients, since it does not need additional loading of tumor-specific antigens.
In addition to being applicable to treatment of AML, the DCOne platform’s most powerful feature is that, upon loading with any kind of TAA, it can be applied to many cancer indications. DCPrime has developed strategies to load the DCOne cell with genes or proteins or peptides from multiple antigens to which an immune response is required. Such antigen-loaded cells can be used alone or in fixed ratios and in different combinations, making the platform broadly applicable.